Skip to content

Study · In vitro (cells) · rat · 1997

2 results

A novel thymosin peptide stimulates interleukin-6 release from rat C6 glioma cells in vitro.

Tijerina M, Gorospe WC, Bowman KL, Badamchian M, Goldstein AL, Spangelo BL

Neuroimmunomodulation1 May 1997Cited by 6 (Europe PMC)

PMID9500150 (opens in a new tab)DOI10.1159/000097334 (opens in a new tab)PepBankPUB-09500150
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In rat C6 glioma cells, thymosin alpha‑1 at 50-1,000 nM had no effect on IL-6 release.

    In plain wordsIn rat brain tumour cells in lab tests, thymosin alpha‑1 did not change release of the inflammatory signal IL-6.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeIL-6 release from C6 glioma cells
    Study

    ratn: not reported in source

    rat C6 glioma cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    50-1,000 nMAs given in this study (rat).

    Measurements

    concentration tested
    50 to 1000 nM
    C6 glioma cells

    Source sentences

    Summary
    Peptides previously purified from TF5 had no effect on IL-6 release at 50-1,000 nM [i.e., thymosin alpha 1 (T alpha 1), thymosin beta 4 (T beta 4), MB35, MB40].
    1 context sentence
    Summary · context
    Therefore, we determined the effects of TF5 on IL-6 release from rat C6 glioma cells in vitro.
  2. 02LabIn vitro (cells)Activity measurement

    In rat C6 glioma cells, thymosin beta‑4 did not change interleukin-6 release.

    In plain wordsIn cells from a rat brain tumor line, thymosin beta‑4 did not change release of the signal protein IL-6.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeIL-6 release from C6 glioma cells
    Study

    ratn: not reported in source

    C6 glioma cells
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    50-1,000 nMAs given in this study (rat).

    Source sentences

    Summary
    Peptides previously purified from TF5 had no effect on IL-6 release at 50-1,000 nM [i.e., thymosin alpha 1 (T alpha 1), thymosin beta 4 (T beta 4
    1 context sentence
    Summary · context
    Glioma cells (25-100 x 10(3)) were exposed to vehicle (RPMI-1640) or TF5 (10-1,000 micrograms/ml) in 96-well plates (200 microliters incubation volume) for 4-24 h to determine optimal cell number and incubation period conditions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.